More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 307.1M
Share based compensation 78.3M
Gain on sale of non-current investments
Other
Movement in deferred taxes 63.1M
Equity in earnings of equity method investees -3.8M
Loss/(gain) on sale of product rights -86.2M
Changes in operating assets and liabilities:
Increase in accounts receivable -92.1M
Increase in sales deduction accrual 28.2M
Increase in inventory -15.8M
Increase in prepayments and other assets -114.7M
Decrease in accounts payable and other liabilities -92.8M
Net cash provided by operating activities 1.67B
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash -32.3M
Purchases of subsidiary undertakings, net of cash acquired -4.1B
Purchases of non-current investments -22.8M
Purchases of property, plant and equipment ("PP&E") -49.8M
Purchases of intangible assets
Proceeds from disposal of non-current investments, PP&E and product rights 21.3M
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -4.01B
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 2.31B
Repayment of debt acquired with ABH -1.46B
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation 37.4M
Proceeds from exercise of options
Payment of dividend -99.6M
Payments to acquire shares by ESOT
Net cash used in financing activities 567.2M
Net (decrease)/increase in cash and cash equivalents -1.77B
Effect of foreign exchange rate changes on cash and cash equivalents -6.2M
Cash and cash equivalents at beginning of period 2.24B
Cash and cash equivalents at end of period 467.7M
Supplemental information associated with continuing operations:
Interest paid 8M
Income taxes paid 76.3M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment